C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study

ConclusionFebuxostat reduced the UA levels but did not affect the CRP levels, and therefore may fail to improve cardiovascular outcomes after treatment.Trial RegistrationClinicalTrial.gov (NCT01984749). https://clinicaltrials.gov/ct2/show/NCT01984749
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research